SUBSCRIBERS

Sanofi to market new haemophilia drug in deal with Alnylam

Published Mon, Jan 8, 2018 · 09:50 PM

Paris

FRENCH pharmaceutical group Sanofi said it has obtained the right to develop and sell a new haemophilia drug in a restructuring of its partnership with Alnylam Pharmaceuticals.

Under the agreement, Sanofi will obtain global development and commercialisation rights to fitusiran, currently in development for the treatment of people with hemophilia A and B.

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes

Consumer & Healthcare

HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue

Companies & Markets

Sanofi to market new haemophilia drug in deal with Alnylam

Consumer & Healthcare

HCA beats first-quarter profit estimates on higher patient admissions

US FDA approves Pfizer’s gene therapy for rare bleeding disorder

EU toughens rules on Chinese fashion retailer Shein

Best World under fire from shareholders at AGM over dividends, director salaries

‘Extreme’ climate blamed for world’s worst wine harvest in 62 years

Sheng Siong Q1 net profit up 9.3% on higher revenue

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

SECTIONS

LIFESTYLE

Follow BT